The factor B inhibitor will be available immediately on the NHS in England and Wales to treat patients with the rare blood disorder that affects approximately ten to 20 people per million worldwide.
PNH patients have an acquired mutation that causes them to produce red blood cells susceptible to premature destruction by the complement system, potentially leading to anaemia, thrombosis, fatigue and other symptoms that can impact quality of life…
